Actuate Therapeutics, Inc. Common stock (ACTU)vsEli Lilly and Company (LLY)
ACTU
Actuate Therapeutics, Inc. Common stock
$1.88
-3.09%
HEALTHCARE · Cap: $47.61M
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
Smart Verdict
WallStSmart Research — data-driven comparison
LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
ACTU
Avoid20
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Trading at 11.7x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACTU
The strongest argument for ACTU centers on Debt/Equity.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ACTU
The primary concerns for ACTU are Price/Book, Revenue Growth, EPS Growth.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Key Dynamics to Monitor
ACTU profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 20/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Actuate Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious diseases, with a particular emphasis on oncology. The company is advancing its proprietary drug candidates through rigorous clinical trials to tackle significant unmet medical needs and improve patient outcomes. By cultivating a robust pipeline focused on transformative therapeutic solutions, Actuate aims to drive strategic growth and deliver substantial value to its investors, reinforcing its competitive stance within the biotechnology sector.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?